LOST Information in Trials (LOST-IT) study Data abstraction Form

reener initials:	Study ID:		Author, year:		
urnal: 🗆 AIM	□ BMJ □ JA	MA	□ Lancet	□ NEJM	
1. Eligible RCT?			e of RCT: Two arms Factorial design Report of secon		☐ Exclude, sto ☐ Multiple Arms ☐ Report of longer follow up ☐ Report of subgroup analy
2. Trial described as:		□ Non-info□ Equival□ Neither	•		
3. Primary outcome clea	rly specified				(go to
		☐ None s	pecified (go to q	4)	
6. Effect on primary end	apoint reported as:	☐ Multino☐ Binary o☐ Binary o	outcome, data	exclusively essed as rate e not available f	
7. Is it a composite endp	oint?	□ Yes, list	components:		
8. Is it a patient importar	nt outcome?	□ No □ Yes, go	to the next ques	tion	□ Exc
9. Result statistically sig	nificant?	□ No □ Yes			□ Exc
Please fill out this box for each s	study	_		e, reason for ex	xclusion:
☐ Include in LOS	T-IT		□ Not RC□ Not elig		
☐ Exclude from L	OST-IT		_	r the primary e	ndpoint not available
☐ 3 rd reviewer r	·	1	□ Outcom	ne not patient ir not statistically	

BACKGROUND INFORMATION										
10.	Number of study centers	n =								
11.	Funding Check all that Apply	 □ Private for profit, industry only supplying medication □ Private for profit, other □ Private not for profit □ Governmental □ Not funded □ Not reported 								
12.	Clinical area Check only one	Medical ☐ Dermatology ☐ Cardiology ☐ Endocrinology ☐ Gastro Intestinal ☐ Hematology ☐ Intensive Care ☐ Infectious Diseases ☐ Neurology ☐ Oncology ☐ Psychiatric ☐ Renal ☐ Respiratory ☐ Rheumatology ☐ Other (specify):	Surgical ☐ Cardiac surgery ☐ General surgery ☐ Obstetrics/ Gynecology ☐ Ophthalmology ☐ Orthopedic surgery ☐ Otorhinolaryngology (ENT: Ear Nose Throat) ☐ Neurosurgery ☐ Plastic surgery ☐ Thoracic surgery ☐ Urologic surgery ☐ Vascular surgery ☐ Other (specify):							
13.	Intervention Check only one Control Check only one	 □ Pharmacological □ Surgery/ Invasive procedure □ Rehabilitation □ Behavioral intervention □ Standard care 	 □ Complementary and alternative medicine □ Diagnostic test □ Other (specify): □ Behavioral intervention 							
	Check only one	□ Placebo□ Pharmacological□ Surgery/ Invasive procedure□ Rehabilitation	□ Complementary and alternative medicine□ Diagnostic test□ Other (specify):							

MET	HODOLOGICAL QUALITY				
15.	Concealment of Allocation Check only one	☐ Sequentially numbered, opaq sealed envelope	☐ Coded medication containers		☐ Central randomization
		☐ Envelopes, other	•	ndom schedule	☐ Quasi-randomized
		"Concealed", no method describe		cealed"	■ Not reported
16.	Blinding of patients	☐ Definitely yes	□ Probably yes	□ Probably n	not Definitely not
17.	Blinding of health Care providers	☐ Definitely yes	□ Probably yes	□ Probably n	not Definitely not
18.	Blinding of data collectors	☐ Definitely yes	□ Probably yes	□ Probably n	not Definitely not
19.	Blinding of outcome adjudicators	☐ Definitely yes	□ Probably yes	□ Probably n	not Definitely not
20.	Blinding of data analysts	☐ Definitely yes	□ Probably yes	□ Probably n	not Definitely not
21.	Study stopped early for benefit	☐ Yes	□ No		
ITT F	PRINCIPLE				
22.	Authors used the term ITT	☐ Yes, "ITT"	☐ Yes, "modified	ITT"	□ No
23.	Post randomization exclusion of mistakenly randomized	☐ Definitely yes	☐ Probably yes	☐ Probably n	ot
24.	Information about ineligibility was available at randomization	☐ Definitely yes	☐ Probably yes	☐ Probably n	ot Definitely not
25.	Post randomization exclusions were blinded to allocation	☐ Definitely yes	☐ Probably yes	☐ Probably n	ot
26.	Patients for whom outcome data is available were analyzed in the arm to which they were randomized	☐ Definitely yes	☐ Probably yes	□ Probably n	ot Definitely not

LIF	U STATEMENTS							
27.	LTFU explicitly reported	■ Explicit statements LTFU occurred	ent:	■ Explicit s LTFU did		■ No explicit statement about LTFU		
28.	CONSORT flow diagram	CONSORT dia showing LTFU	gram	CONSO not show	RT diagram ng LTFU	■ No CONSORT diagram		
29.	For studies with no explicit statement about LTFU and no consort diagram	☐ Meet all "3 cr (see instructions		□ Does no criteria" instruction	t meet all "3 (see ns)			
30.	LTFU reported separately for the 2 arms	☐ Yes ☐ No						
31.	LTFU reported for each time point in which effect estimate for 1 ^{ary} outcome is reported in this article	□ Yes		□ No		■ N/A (only one effect estimate reported)		
32.	Authors compared baseline characteristics of LTFU	☐ Yes, LTFU group vs. ☐ Yes, LTFU 1st arm vs. LTFU 2nd arm			n □ No			
33.	Implications of LTFU discussed	☐ Yes		□ No				
34.	Method of dealing with LTFU explicitly described (check all that apply)	☐ Yes, survival analysis		☐ Yes, in		□ No		
35. I	METHOD OF DEALING WITH LTFU (f							
	WETHOD OF DEALING WITH EITO (7	or the primary outco	me)					
	Method	or the primary outco		Primary and neck at least and		Additional analyses (check all applicable)		
	Method Not applicable, no LTFU occurred							
	Method Not applicable, no LTFU occurred Not applicable, uncertain whether LTF					(check all applicable)		
	Method Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used	U occurred		eck at least and		(check all applicable)		
	Method Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time	U occurred		neck at least and		(check all applicable)		
	Method Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis	U occurred		neck at least and		(check all applicable)		
	Method Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario	U occurred		neck at least and		(check all applicable)		
	Method Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario	U occurred		eck at least and		(check all applicable)		
	Method Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario None of the LFTU had the outcome	U occurred		neck at least and		(check all applicable)		
	Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario None of the LFTU had the outcome All LTFU had the outcome	U occurred e of LTFU)		eck at least and		(check all applicable)		
	Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario None of the LFTU had the outcome All LTFU had same outcome incidence as	U occurred e of LTFU) s their group	(ch	eck at least and		(check all applicable)		
	Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario None of the LFTU had the outcome All LTFU had the outcome LTFU had same outcome incidence as	U occurred e of LTFU) s their group	(ch	eck at least and		(check all applicable)		
	Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario None of the LFTU had the outcome All LTFU had same outcome incidence as	of LTFU) s their group han their group, sam	(ch	eck at least and		(check all applicable)		
	Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario None of the LFTU had the outcome All LTFU had the outcome LTFU had same outcome incidence as LTFU had higher outcome incidence to incidence in 2 study groups LTFU had higher outcome incidence to different incidence in 2 study groups	s their group han their group,	(ch	eck at least and		(check all applicable)		
	Not applicable, no LTFU occurred Not applicable, uncertain whether LTF Unclear which method used Survival analysis (censored at the time Complete case analysis Worst case scenario Best case scenario None of the LFTU had the outcome All LTFU had the outcome LTFU had same outcome incidence as LTFU had higher outcome incidence to incidence in 2 study groups LTFU had higher outcome incidence to	s their group han their group,	(ch	eck at least and		(check all applicable)		

LTF	LTFU STATISTICAL DATA													
36.	36. Primary outcome selected for LOST-IT (q3 or q4):													
07	☐ Check here if outco		om positive to ne	egative										
	37. Follow-up time point (value):													
	Unit of time:	3							reeks □ months □ years					
39.	Type of fileasure:	□ lixeu periou	□ mean		U 11111):tt	1			
	This table relates to the <u>primary analysis</u> of the <u>primary outcome</u>					Intervention	Control	Total	for of L	diffe TFU	eren J (cii	t sul rcle	sumption bgroups one tructions	S
40.	☐ Mistakenly rand	domized, inapprop	riately exclud	led (subtotal 1)					1	2	3	4	5	
41.	☐ Did not receive	intervention, inap	propriately ex	kcluded (subtot	al 2)				1	2	3	4	5	
42.	☐ Withdrew cons	ent (subtotal 3)												
	□ unclear whethe	er followed up												
	$\hfill\Box$ not followed up													
	\square followed up, no	t included in the anal	ysis (not LTFU t	for LOST-IT)										
43.	Withdrew conser	nt due to side effect o	r adverse events	S					1	2	3	4	5	
44.	4. Withdrew consent due to other specified reason:								1	2	3	4	5	
45.	Withdrew conser	nt due to unclear reas	on						1	2	3	4	5	
46.	☐ Cross over (sul	btotal 4)												
	□ unclear whethe	•												
	□ not followed up													
		t included in the analy	,	•	CT IT\									
47	•	alyzed in a group not of side effect or adverse		(NOLLIFU IOLLU)	51-11)				1	2	2	4	<u> </u>	
47.		o other specified reas								2				
48.	Cross over due to		OUII.							2		4		
49.									'		3	4	J	
50.	□ Non adherent (ŕ												
	☐ unclear whethe	•												
	☐ not followed up	t included in the anal	usis (not l TFII f	for LOST-IT)										
	•	alyzed in a group not			ST-IT)									
51.	•	e to side effect or adv			,				1	2	3	4	5	
52.		e to other specified re							1	2	3		5	
53.		e to unclear reason	JUJUII.						1		3		5	
54.		nd no other source	of outcome	data (cubtotal 4))				1	2		4		
54.	LUST CUITACT AL	ia no otner source	or outcome (uata (Subtutat 0)	,				'	-	J	•	J	

55.	☐ Other (or no reported) reason for LTFU:				1 2	3 4 5	
	□ unclear whether followed up						
	□ not followed up						
	$\ \square$ followed up, not included in the analysis (not LTFU for LOST-IT)						
56.	☐ Different categories of LTFU reported together:				1 2	3 4 5	
	□ unclear whether followed up						
	□ not followed up						
	$\ \square$ followed up, not included in the analysis (not LTFU for LOST-IT)						
57.	LTFU, total						
	This table relates to the <u>primary analysis</u> of the <u>primary outcome</u>	Interve		Contro)l 	Total	,
		Total	Events	Total	Events	Total	Events
58.	Mistakenly randomized, appropriately excluded						
59.	Did not receive intervention, appropriately excluded						
60.	Excluded as part of center exclusion						
61.	Randomized						
62.	Randomized\$ (Randomized – appropriately excluded 61-(58+59+60))						
63.	Included in primary analysis						
64.	Followed-up						
65.	Measure of effect estimate	□RR		□HR	□OR		RRR
		□ARR	/ARI I	□Time ratio	□Cum ratio	ulative in	cidence
66.	Unadjusted Effect estimate; 95% CI; p value		_ (·);	p=	
67.	Adjusted Effect estimate; 95% CI; p value		_ ();	p=	
68.	Inconsistency in LTFU data (explain below)						
69.	Misunderstanding of LTFU or questionable inferences (explain below)						
70.	Time required to complete this form: min						
71.	☐ Check here if we need to ask authors for numbers per study arm (if	only tota	al numl	bers reno	rted)		
	☐ Check here if we need to ask authors for the total number of LTFU	-		-	,		